Bazedoxifene is now being repositioned as a new strategy for treating multiple cancer types (such as breast cancer, pancreatic cancer, colon cancer, etc.)by downregulating anti-apoptotic proteins such as BCL-2 [84]. Here, BCL2 is linked to familial pancreatic carcinoma.